Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Digoxin in Modern Heart Failure Treatment
2024-513448-26-00Phase 4Completed
- Sponsor
- ULS São José
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of digoxin in heart failure with reduced ejection fraction (HFrEF), sponsored by ULS São José. Primary endpoints: Peak oxygen consumption at 24 weeks and Global Work Index at 24 weeks. Started Sep 2024; status: completed.
02
Drugs
digoxin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2024-513448-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513448-26-00.